Biometric changes and endothelial cell loss after deep sclerectomy and trabeculectomy

Ophthalmology Times EuropeOphthalmology Times Europe January / February 2022
Volume 18
Issue 01

Comparisons of deep sclerectomy and trabeculectomy show the former to have better outcomes and fewer complications in cases where it is indicated.

Biometric changes and endothelial cell loss after deep sclerectomy and trabeculectomy

In recent decades, safety concerns have fuelled progress in glaucoma surgery techniques. Standard trabeculectomy (TE) has well-known complications such as hypotony; choroidal detachment; flat anterior chamber; hyphema; acute or late endophthalmitis; and, in some cases, surgery-induced cataract.

Many new methods, including non-penetrating surgical procedures, have been developed in the search for an alternative approach. Deep sclerectomy (DS) has become one of the most widely used non-penetrating surgeries in primary open-angle glaucoma (POAG), and there is good evidence as to its efficacy and safety.1

In DS, removing the inner wall of Schlemm’s canal and the juxta-canalicular trabecular meshwork enhances aqueous outflow. The trabeculo-Descemet’s membrane (TDM) remains intact to control and prevent excessive aqueous outflow, which offers an advantage in comparison with TE.

The low complication rates of DS offer an opportunity to perform the surgery at an earlier stage of glaucoma, and it can be considered as first-line therapy in cases when eye drops are not enough to control the IOP or if laser treatment is unavailable.2 DS can also be considered if the compliance of the patient is uncertain.

Furthermore, DS is preferred in uveitic glaucoma with open angle as it causes less inflammation than penetrating procedures.3 Another indication with which DS is the more appropriate choice of procedure is high myopia, which has a higher risk of choroidal detachment.4

In the presence of risk factors for inflammation such as chronic blepharitis, or for patients with dementia, DS could be considered to reduce the risk of endophthalmitis. Cataract surgery in glaucoma patients is a good indication to reduce the IOP through combined surgery (phaco with DS).5–7 On the other hand, neovascular glaucoma is considered as a contraindication to DS, since the TDM filtration can be decreased or stopped by the fibrovascular membrane over the irido-corneal angle.

Similarly, cases of iridocorneal endothelial syndrome are contraindicated for DS. A narrow angle is considered as a relative contraindication because of possible anterior synechia formation or iris incarceration following surgery.8 Eyes with damaged trabeculae (e.g., post-traumatic angle recession, post-laser trabeculoplasty) are also relatively contraindicated for DS, as surgical success depends on the integrity of angle structures.1

The different biometric changes following TE and DS, which may be important in cases such as combined surgery, are discussed as follows.

Biometric changes after TE and DS


Claridge et al. studied and controlled 29 patients admitted for TE.9 Subjective and automatedrefraction, manual keratometry and corneal topography were assessed pre- and postoperatively, and the results confirm that glaucoma surgery has an influence on astigmatism.

After TE there was an increase in vertical keratometry producing with-the-rule (WTR) astigmatism. Moreover, the topographic changes lasted for at least 12 months after surgery. These changes could have a significant effect on visual function in some patients.9

Rosen et al. used corneal topography preoperatively and at 12 weeks postoperatively to show a WTR shift of 1.5–2.5 D of cylinder, which was underestimated by keratometry.10 This was thought to relate to tight sutures, excessive cautery or a large drainage bleb.9 This change in astigmatism would interfere with precise measurement of the IOL in combined surgery.

On the other hand, in a report by Corcosteguiet al. reviewing 38 eyes of 35 patients, there was no clinically significant refractive change following phaco-DS surgery.11 This could be down to the flat bleb after DS. Moreover, the sutures in DS should not be tight like those in TE. A recent review by Chan et al. suggests that the astigmatism change stabilises at 3 months after TE.12

Anterior chamber depth

Anterior chamber depth (ACD) is another variable after glaucoma surgery. Husain et al. analysed 122 patients over 5 years after TE and found that the mean decrease in ACD from baseline was 0.11 mm at all postoperative visits.13

However, Bouhéraouaet al.evaluated parameters including ACD in 20 eyes of 20 patients who underwent DS for POAG. Measurements were taken 1 day pre-op, then on days 1, 7 and 30 post-op, and surgery was not found to affect ACD.14 This could be a result of the controlled filtration through TDM in DS.

Axial length

Husain et al. reported that, 5 years after TE, axial length (AL) was shorter by about 0.16 mm compared with the value before surgery.13 This has an effect of about 0.4 D, which is sometimes significant visually.

On the other hand, García et al., who studied 22 patients who had undergone DS, reported that the decrease in AL 1 year after DS was 0.08 mm.15 The difference is thought to be related to the amount of filtration after glaucoma surgery.

Endothelial cell loss

Phaco surgery can result in damage to the endothelium in the cornea.16 Glaucoma surgery is another well-known cause of endothelial cell loss (ECL), but it occurs less with DS than with TE.

Arnavielleet al. studied 62 eyes of 62 patients and reported ECL values of 7% after TE and 2.6% after DS 3 months after surgery, then, 12 months after surgery, 9.6% with TE and 4.5% with DS.17 Some surgeons prefer to include paracentesis in DS surgery to reduce the aqueous humour in the anterior chamber, which reduces the chances of perforating the TDM. This may be the cause of more ECL in DS.

Reduced endothelial cell count may lead to corneal decompensation in the long term and this should be considered in combined surgery: it is wise to measure the endothelial cell count before surgery. Regardless of this, DS offers an advantage to the patient with reduced endothelial cell count.

Overall, DS has many advantages that may make glaucoma surgery or combined surgery in many patients safer and more successful. This is particularly relevant in developing countries, where minimally-invasive glaucoma surgery (MIGS) might be difficult to afford or unavailable; also, MIGS might not reduce the IOP enough to reach the target pressure.

Abdelwahhab Azzawi, MD, FEBO, MRCPS (Glasg)
Dr Azzawi is head of the Azzawi clinic in Grossenhain in Sachsen, Germany ( He has no financial disclosures.
1. Sarodia U, Shaarawy T, Barton K. Nonpenetrating glaucoma surgery: a critical evaluation. Curr Opin Ophthalmol. 2007;18:152-158.
2. Varga Z and Shaarawy T. Deep sclerectomy: safety and efficacy. Middle East Afr J Ophthalmol. 2009;16:123-126.
3. Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53:592-630.
4. Hamel M, Shaarawy T, Mermoud A. Deep sclerectomy with collagen implant in patients with glaucoma and high myopia. J Cataract Refract Surg. 2001;27:1410-1417.
5. Mercieca K, Shevade B, Anand N. Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study. Eye (Lond). 2015;29:1495-1503.
6. Muñoz Negrete FJ, Rebolleda G, Noval S. Non-penetrating deep sclerectomy combined with phacoemulsification. Results and complications. Arch Soc Esp Oftalmol. 2003;78:499-506.
7. Bilgin G, Karakurt A, Saricaoglu MS. Combined non-penetrating deep sclerectomy with phacoemulsification versus non-penetrating deep sclerectomy alone. Semin Ophthalmol. 2014;29:146-150.
8. Roy S, Mermoud A. Deep sclerectomy. Dev Ophthalmol. 2012;50:29-36.
9. Claridge KG, Galbraith JK, Karmel V, Bates AK. The effect of trabeculectomy on refraction, keratometry and corneal topography. Eye (Lond). 1995;9:292-298.
10. Rosen WJ, Mannis MJ, Brandt JD. The effect of trabeculectomy on corneal topography. Ophthalmic Surg. 1992;23:395-398.
11. Corcostegui J, Rebolleda G, Muñoz-Negrete FJ. Refractive changes after phacoemulsification combined with deep sclerectomy assisted by corneal topography. J Cataract Refract Surg. 2004;30:2391-2396.
12. Chan HHL, Kong YXG. Glaucoma surgery and induced astigmatism: a systematic review. Eye Vis (Lond). 2017;4:27.
13. Husain R, Li W, Gazzard G, et al. Longitudinal changes in anterior chamber depth and axial length in Asian subjects after trabeculectomy surgery. Br J Ophthalmol. 2013;97:852-856.
14. Bouhéraoua N, Hamard P, Iordanidou V, et al. Assessment of anterior segment anatomy by OCT after non penetrating deep sclerectomy. J Fr Ophtalmol. 2012;35:760-767.
15. García García MÁ, Doménech B, Palacios KS, et al. Axial length changes after glaucoma deep sclerectomy surgery. JSM Ophthalmol. 2016;4:1043.
16. Walkow T, Anders N, Klebe S. Endothelial cell loss after phacoemulsification: relation to preoperative and intraoperative parameters. J Cataract Refract Surg. 2000;26:727-732.
17. Arnavielle S, Lafontaine PO, Bidot S, et al. Corneal endothelial cell changes after trabeculectomy and deep sclerectomy. J Glaucoma. 2007;16:324-328.
Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.